Quick Answer ADC Therapeutics SA reported Stockholders Equity of -$185.83 million for fiscal year 2025. ADC Therapeutics SA Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$185.83M +8.3% 2024 -$202.64M -36.7% 2023 -$148.25M -286.6% 2022 $79.45M -48.4% 2021 $154.03M — Quarterly Stockholders Equity Quarter Ending Stockholders Equity YoY QoQ September 30, … Read more
Quick Answer ADC Therapeutics SA reported Cash and Equivalents of $261.34 million for fiscal year 2025. ADC Therapeutics SA Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $261.34M +4.2% 2024 $250.87M -10.0% 2023 $278.60M -14.7% 2022 $326.44M — Quarterly Cash and Equivalents Quarter Ending Cash and Equivalents YoY QoQ … Read more
Quick Answer ADC Therapeutics SA reported Diluted EPS of $1.12 per share (loss) for fiscal year 2025. ADC Therapeutics SA Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$1.12 +30.9% 2024 -$1.62 +44.9% 2023 -$2.94 -46.3% 2022 -$2.01 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ September 30, 2025 … Read more
Quick Answer ADC Therapeutics SA reported Total Assets of $323.15 million for fiscal year 2025. ADC Therapeutics SA Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $323.15M +0.4% 2024 $321.98M -9.2% 2023 $354.78M -27.7% 2022 $490.86M -20.6% 2021 $617.97M +20.3% 2020 $513.69M +273.1% 2019 $137.68M — Quarterly Total Assets Quarter Ending … Read more
Quick Answer ADC Therapeutics SA reported Net Income of -$142.62 million for fiscal year 2025. ADC Therapeutics SA Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$142.62M +9.6% 2024 -$157.85M +34.2% 2023 -$240.05M -52.8% 2022 -$157.13M — Quarterly Net Income Quarter Ending Net Income YoY QoQ September 30, 2025 -$40.97M +6.8% … Read more
Quick Answer ADC Therapeutics SA reported Total Revenue of $81.36 million for fiscal year 2025. ADC Therapeutics SA Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $81.36M +14.9% 2024 $70.84M +1.8% 2023 $69.56M -66.9% 2022 $209.91M — Quarterly Total Revenue Quarter Ending Total Revenue YoY QoQ September 30, 2025 $16.43M -11.0% … Read more
Quick Answer ADC Therapeutics SA reported Revenue (ASC 606) of $69.06 million for fiscal year 2023. ADC Therapeutics SA Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2023 $69.06M -7.8% 2022 $74.91M — Quarterly Revenue (ASC 606) Quarter Ending Revenue (ASC 606) YoY QoQ September 30, 2025 $15.75M -12.6% -12.9% … Read more
Quick Answer ADC Therapeutics SA reported Total Revenue of $81.36 million for fiscal year 2025. ADC Therapeutics SA — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $81.36M+14.9% $70.84M+1.8% $69.56M-66.9% $209.91M — — Revenue (ASC 606) — — $69.06M-7.8% $74.91M — — Net Income -$142.62M+9.6% -$157.85M+34.2% -$240.05M-52.8% -$157.13M — — … Read more
Quick Answer AGREE REALTY CORP reported Shares Outstanding of 120.03 million shares for fiscal year 2025. AGREE REALTY CORP Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 120.03M +11.9% 2024 107.25M +6.7% 2023 100.52M +11.5% 2022 90.17M +26.5% 2021 71.29M +18.8% 2020 60.02M +31.7% 2019 45.57M +21.4% 2018 37.55M +21.1% 2017 … Read more
Quick Answer AGREE REALTY CORP reported Stockholders Equity of $6.27 billion for fiscal year 2025. AGREE REALTY CORP Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $6.27B +13.8% 2024 $5.51B +6.0% 2023 $5.20B +12.3% 2022 $4.63B +35.4% 2021 $3.42B +35.4% 2020 $2.52B +49.4% 2019 $1.69B +36.7% 2018 $1.24B +36.0% 2017 $908.66M … Read more